.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,425,934

« Back to Dashboard

Claims for Patent: 8,425,934

Title:Pharmaceutical compositions
Abstract: The present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.]}-3-(7-{[2-(3,4-difluorop- henyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-- 3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.
Inventor(s): Banks; Simon (Loughborough, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:11/841,030
Patent Claims: 1. A pharmaceutical composition comprising: {1S-[1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.]}-3-(7-{[2-(3,4-difluorop- henyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-- 3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol as the active ingredient; and further comprising: a filler consisting essentially of a mixture of mannitol and dibasic calcium phosphate dihydrate; a binder consisting essentially of hydroxypropyl cellulose; a disintegrant consisting essentially of sodium starch glycolate; and one or more lubricants.

2. A pharmaceutical composition according to claim 1 wherein the lubricant is magnesium stearate or sodium stearyl fumarate.

3. A pharmaceutical composition according to claim 1 wherein {1S-[1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.]}-3-(7-{[2-(3,4-difluorop- henyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-- 3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol is present in an amount of 20 to 45% by weight of the pharmaceutical composition as a whole.

4. A pharmaceutical composition according to claim 1 wherein the filler is present in an amount of 20 to 70% by weight of the pharmaceutical composition as a whole.

5. A pharmaceutical composition according to claim 1 wherein the binder is present in an amount of 3 to 6% by weight of the pharmaceutical composition as a whole.

6. A pharmaceutical composition according to claim 1 wherein the disintegrant is present in an amount of 2 to 6% by weight of the pharmaceutical composition as a whole.

7. A pharmaceutical composition according to claim 1 wherein the lubricant is present in an amount of 0.5 to 1% by weight of the pharmaceutical composition as a whole.

8. A pharmaceutical composition according to claim 1 wherein {1S-[1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.]}-3-(7-{[2-(3,4-difluorop- henyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-- 3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol is substantially present in the form of Polymorph II.

9. A pharmaceutical composition according to claim 1 wherein {1S-[1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.]}-3-(7-{[2-(3,4-difluorop- henyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-- 3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol is substantially present in the form of Polymorph III.

10. A pharmaceutical composition according to claim 1 wherein: the lubricant is magnesium stearate.

11. A pharmaceutical composition according to claim 1 comprising: {1S-[1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.]}-3-(7-{[2-(3,4-difluorop- henyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-- 3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol in an amount of 20 to 45% by weight of the pharmaceutical composition as a whole; mannitol in an amount of 20 to 45% by weight of the pharmaceutical composition as a whole; dibasic calcium phosphate dihydrate in an amount of 10 to 30% by weight of the pharmaceutical composition as a whole; hydroxypropylcellulose in an amount of 3 to 6% by weight of the pharmaceutical composition as a whole; sodium starch glycolate in an amount of 2 to 6% by weight of the pharmaceutical composition as a whole; and lubricant in an amount of 0.5 to 3% by weight of the pharmaceutical composition as a whole.

12. A pharmaceutical composition according to claim 1 which has been prepared by a wet granulation process.

13. A pharmaceutical composition according to claim 1 which has been prepared by a high shear wet granulation process.

14. A pharmaceutical composition according to claim 1 wherein the combined amount of filler, binder, and disintegrant is 50 to 90% by weight of the pharmaceutical composition as a whole.

15. A pharmaceutical composition according to claim 1 wherein the active ingredient is admixed with filler, binder, disintegrant, and one or more lubricants.

16. A pharmaceutical composition according to claim 1 wherein the composition is a tablet.

17. A pharmaceutical composition according to claim 1 wherein the composition is a core tablet.

18. An oral immediate release pharmaceutical composition comprising: {1S-[1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.]}-3-(7-{[2-(3,4-difluorop- henyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-- 3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol substantially present in the form of Polymorph II in an amount of 20 to 45% by weight of the pharmaceutical composition as a whole; mannitol in an amount of 20 to 45% by weight of the pharmaceutical composition as a whole; dibasic calcium phosphate dihydrate in an amount of 10 to 30% by weight of the pharmaceutical composition as a whole; hydroxypropyl cellulose in an amount of 3 to 6% by weight of the pharmaceutical composition as a whole; sodium starch glycolate in an amount of 2 to 6% by weight of the pharmaceutical composition as a whole; and one or more lubricants in an amount of 0.5 to 3% by weight of the pharmaceutical composition as a whole.

19. An oral pharmaceutical composition consisting of: {1S-[1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.]}-3-(7-{[2-(3,4-difluorop- henyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-- 3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol substantially present in the form of Polymorph II in an amount of 20 to 45% by weight of the pharmaceutical composition as a whole; mannitol in an amount of 20 to 45% by weight of the pharmaceutical composition as a whole; dibasic calcium phosphate dihydrate in an amount of 10 to 30% by weight of the pharmaceutical composition as a whole; hydroxypropyl cellulose in an amount of 3 to 6% by weight of the pharmaceutical composition as a whole; sodium starch glycolate in an amount of 2 to 6% by weight of the pharmaceutical composition as a whole; and one or more lubricants in an amount of 0.5 to 3% by weight of the pharmaceutical composition as a whole.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc